drugset / Trial / NCT06864052
The Incidence of New-brain Lesions on Brain MRI and Safety Between Edoxaban and Apixaban in Patients with Stroke and Nonvalvular Atrial Fibrillation
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to determine whether there is a difference in brain lesion occurrence and safety when brain MRI is followed up between edoxaban and apixaban in stroke patients with nonvalvular atrial fibrillation through exploratory clinical trials.
Timeline
- Start
- 2025-03-01
- Primary completion
- 2029-09-30
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apixaban | Small molecule | 2.5 mg | — |
| Subject | Apixaban | Small molecule | 5 mg | — |
| Subject | Edoxaban | Small molecule | 15 mg | — |
| Subject | Edoxaban | Small molecule | 30 mg | — |
| Subject | Edoxaban | Small molecule | 60 mg | — |